Scandion Oncology A/S (SCOL.ST)
SEK 0.08
(-6.78%)
SEK 0.08
(-6.78%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -26.02 Million DKK | 65.77% |
| 2022 | -76 Million DKK | 27.26% |
| 2021 | -104.48 Million DKK | -1800.45% |
| 2020 | -5.49 Million DKK | 64.34% |
| 2019 | -15.41 Million DKK | -101.24% |
| 2018 | -7.66 Million DKK | -367.87% |
| 2017 | -1.63 Million DKK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -26.77 Million DKK | -60.44% |
| 2024 Q1 | -16.68 Million DKK | 35.87% |
| 2023 Q2 | -44.5 Million DKK | 24.29% |
| 2023 Q3 | -35.7 Million DKK | 19.76% |
| 2023 FY | -26.02 Million DKK | 65.77% |
| 2023 Q1 | -58.78 Million DKK | 22.66% |
| 2023 Q4 | -26.02 Million DKK | 27.13% |
| 2022 Q2 | -71.86 Million DKK | 17.38% |
| 2022 FY | -76 Million DKK | 27.26% |
| 2022 Q4 | -76 Million DKK | 16.23% |
| 2022 Q3 | -90.73 Million DKK | -26.27% |
| 2022 Q1 | -86.98 Million DKK | 16.76% |
| 2021 Q4 | -104.48 Million DKK | 10.97% |
| 2021 Q2 | -131.54 Million DKK | 9.42% |
| 2021 Q1 | -145.21 Million DKK | -2541.25% |
| 2021 FY | -104.48 Million DKK | -1800.45% |
| 2021 Q3 | -117.36 Million DKK | 10.78% |
| 2020 Q2 | -7.27 Million DKK | 33.93% |
| 2020 Q3 | -7.5 Million DKK | -3.15% |
| 2020 FY | -5.49 Million DKK | 64.34% |
| 2020 Q4 | -5.49 Million DKK | 26.74% |
| 2020 Q1 | -11.01 Million DKK | 28.58% |
| 2019 Q3 | -18.02 Million DKK | -470.44% |
| 2019 Q2 | -3.16 Million DKK | 40.16% |
| 2019 Q1 | -5.28 Million DKK | 31.07% |
| 2019 Q4 | -15.41 Million DKK | 14.47% |
| 2019 FY | -15.41 Million DKK | -101.24% |
| 2018 Q2 | -327.12 Thousand DKK | 0.0% |
| 2018 Q3 | 255.84 Thousand DKK | 178.21% |
| 2018 Q4 | -7.66 Million DKK | -3094.89% |
| 2018 FY | -7.66 Million DKK | -367.87% |
| 2017 Q4 | -1.63 Million DKK | 0.0% |
| 2017 FY | -1.63 Million DKK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Lipum AB (publ) | -8.46 Million SEK | -207.395% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 47.98% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -36.522% |
| BioArctic AB (publ) | -606.58 Million SEK | 95.71% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 47.889% |
| Mendus AB (publ) | -96.29 Million SEK | 72.978% |
| Intervacc AB (publ) | -88.16 Million SEK | 70.484% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 226.87% |
| Active Biotech AB (publ) | -33.2 Million SEK | 21.623% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 148.891% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 33.927% |
| Aptahem AB (publ) | 2.9 Million SEK | 994.61% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 92.2% |
| Kancera AB (publ) | -45.69 Million SEK | 43.051% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 92.092% |
| Fluicell AB (publ) | -2.76 Million SEK | -841.766% |
| Saniona AB (publ) | 40.44 Million SEK | 164.334% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 18.498% |
| Biovica International AB (publ) | -58.73 Million SEK | 55.699% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 42.453% |
| AcouSort AB (publ) | -23.98 Million SEK | -8.484% |
| Xintela AB (publ) | -7.8 Million SEK | -233.218% |
| Ziccum AB (publ) | -2.13 Million SEK | -1117.642% |
| Genovis AB (publ.) | -43.94 Million SEK | 40.782% |
| Abliva AB (publ) | -57.24 Million SEK | 54.541% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 86.635% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 68.345% |
| OncoZenge AB (publ) | -12.62 Million SEK | -106.074% |
| CombiGene AB (publ) | -101.44 Million SEK | 74.348% |
| Camurus AB (publ) | -1.16 Billion SEK | 97.767% |
| Corline Biomedical AB | -17.01 Million SEK | -52.957% |
| Amniotics AB (publ) | -5.63 Million SEK | -362.021% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 68.928% |
| 2cureX AB (publ) | -13.4 Million SEK | -94.143% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -1104.118% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 581.87% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 79.906% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 11.442% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 81.164% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -96.694% |
| I-Tech AB | -83.26 Million SEK | 68.748% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 119.317% |
| Cyxone AB (publ) | -16.67 Million SEK | -56.095% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 53.439% |
| Biosergen AB | -1.88 Million SEK | -1281.891% |
| Cantargia AB (publ) | -139.74 Million SEK | 81.38% |
| NextCell Pharma AB | -46.79 Million SEK | 44.388% |
| Nanologica AB (publ) | -9.38 Million SEK | -177.173% |
| SynAct Pharma AB | -61.75 Million SEK | 57.866% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -21.508% |
| LIDDS AB (publ) | -13.51 Million SEK | -92.577% |
| BioInvent International AB (publ) | -236.3 Million SEK | 88.988% |
| Alzinova AB (publ) | -21.22 Million SEK | -22.59% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 61.116% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 68.927% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -402.247% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -2719.177% |
| Simris Alg AB (publ) | 85.07 Million SEK | 130.586% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 68.3% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 115.668% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -25.143% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -775.538% |